SIGLEC family like 1Genealiases: C19orf75 · SIGLEC23P · SIGLECP7
Q-omics provides the consensus-scored SIGLECL1 profile across patient tissues and cancer cell-line models. SIGLECL1 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, SIGLECL1 is differentially expressed in 5, with the highest sampling consensus in BRCA. Additionally, SIGLECL1 RNA expression shows 7,075 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight DLBC, BRCA, and TGCT as cancer lineages where SIGLECL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SIGLECL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SIGLECL1 survival associations across molecular data types. SIGLECL1 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SIGLECL1 RNA expression–survival associations across cancer types. High SIGLECL1 expression shows unfavorable associations in DLBC, READ, UVM, MESO and KIRC, but favorable associations in SARC. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify DLBC as the clearest survival context for SIGLECL1 RNA expression.
This table summarizes SIGLECL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for SIGLECL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SIGLECL1 shows lower tumor expression in BRCA and STAD and higher tumor expression in KIRP, LUAD and LIHC. The BRCA box plot shows higher SIGLECL1 RNA expression in normal versus tumor tissue (log2 FC = −0.010, t-test p = .002).
This table shows molecular features associated with SIGLECL1 in patient tissues and cancer cell lines. In patient samples, SIGLECL1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SIGLECL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
